3.4 points Save and Question 29 APP cash equal in value to the excess of the market price at exercise over the share price at the date of expected to remain employed through the vesting date. The fair value of the SARS, estimated by an appropriate option pricing model, is 56 per SAR at December 31, 2021. If the fair value was re-estimated at December The SARS cannot be exercised until the end of 2024 (vesting date) and expire at the end of 2026. Recipients are 31, 2022 to be $10, the compensation expense for 2022 was: $35 million $227 million $25 million $15 milion Question 29 of 30 >>>